Objective To discuss the value of rabeprazole combined with anti Helicobacter pylori therapy for gastric ulcers.Methods 108 patients with gastric ulcers were randomly divided into a control group(n=54,omeprazole combined with amoxicillin treatment)and a study group(n=54,rabeprazole combined with anti Helicobacter pylori therapy).The clinical indicators,treatment effect,inflammatory factors and adverse reactions were compared between the two groups.Results The study group interleukin-1β(IL-1β)of(0.17±0.03)ng/ml,gastrin-releasing peptide(GRP)of(2.96±0.8)μg/ml and gastrin(GAS)of(75.23±4.71)ng/L,which were lower than(0.34±0.02)ng/ml,(6.35±1.36)μg/ml and(93.31±5.48)ng/L in the control group;the study group had higher somatostatin(SS)of(46.05±3.67)ng/L than(37.98±2.58)ng/L in the control group(P<0.05).The total effective rate of the study group was 98.15%,which was significantly higher than 87.04%of the control group(P<0.05).After treatment,the study group had tumor necrosis factor-α(TNF-α)of(8.10±0.60)pg/ml,interleukin-6(IL-6)of(28.50±1.40)pg/ml and interleukin-10(IL-10)of(12.20±1.60)ng/L,which were significantly lower than(8.90±0.80)pg/ml,(30.30±1.70)pg/ml and(13.20±1.30)ng/L in the control group(P<0.05).The incidence of adverse reactions in the study group was 5.56%,which was lower than 18.52%in the control group(P<0.05).Conclusion The combination of rabeprazole and anti Helicobacter pylori therapy has a significant therapeutic effect on gastric ulcer patients.
维普
万方数据
